A Center for Stem Cells, Genomics, Software, Neuroscience
Summary
But biotechnology today actually requires what you might call a triple helix of money, people, and ideas, according to John Mendlein, the chairman of San Diego-based Fate Therapeutics.It partly comes from the fact that we have so many institutions here [that] are private and small.” Rusty Gage on the current trend he sees among venture capitalists: “It’s almost as if the investors don’t have as much confidence anymore as they used to.The thing scientists worry about is that when you have a good idea, and you want to move it forward, there’s a sense that you need to have a Phase I clinical trial ready to go.I understand the driver for that, but I think there should be caution around moving too quickly.” Bradbury on new attitudes toward investment coming out of the downturn: “Who makes up the venture community now is changing.If you look at stem cells here, the Center for Regenerative Medicine, the way that was created with UCSD, Scripps, Salk, (Sanford Burnham), all working together, that’s probably pretty unique to San Diego.
Classifications
AskAI Classifications
LabelsLinked Companies
